Summit Therapeutics (SMMT) Stock Forecast, Price Target & Predictions
SMMT Stock Forecast
Summit Therapeutics stock forecast is as follows: an average price target of $35.00 (represents a 90.01% upside from SMMT’s last price of $18.42) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
SMMT Price Target
SMMT Analyst Ratings
Buy
Summit Therapeutics Price Target by Analyst
Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
---|---|---|---|---|---|---|
Nov 04, 2024 | Reni Benjamin | JMP Securities | $32.00 | $19.96 | 60.32% | 73.72% |
Sep 27, 2024 | Yigal Nochomovitz | Summit Redstone Partners | $23.00 | $20.89 | 10.13% | 24.86% |
Sep 25, 2024 | Brad Canino | Stifel Nicolaus | $40.00 | $24.00 | 66.67% | 117.16% |
Sep 16, 2024 | Mitchell Kapoor | H.C. Wainwright | $45.00 | $31.93 | 40.93% | 144.30% |
Jun 03, 2024 | Brad Canino | Stifel Nicolaus | $14.00 | $8.69 | 61.20% | -24.00% |
Mar 25, 2024 | Brad Canino | Stifel Nicolaus | $8.00 | $3.28 | 143.90% | -56.57% |
10
Summit Therapeutics Price Target by Period
1M | 3M | 12M | |
---|---|---|---|
# Anlaysts | 1 | 4 | 6 |
Avg Price Target | $32.00 | $35.00 | $27.00 |
Last Closing Price | $18.42 | $18.42 | $18.42 |
Upside/Downside | 73.72% | 90.01% | 46.58% |
Analyst Ratings Upgrades/Downgrades
Date | Company | Previous Rating | New Rating | Rating Change |
---|---|---|---|---|
Nov 04, 2024 | JMP Securities | - | Market Outperform | Initialise |
Oct 31, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Oct 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Sep 27, 2024 | Citigroup | Buy | Neutral | Downgrade |
Sep 09, 2024 | Citigroup | Buy | Buy | Hold |
Sep 03, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Aug 12, 2024 | H.C. Wainwright | - | Buy | Initialise |
Jul 19, 2024 | Citigroup | Buy | Buy | Hold |
May 31, 2024 | Citigroup | Buy | Buy | Hold |
May 07, 2024 | Citigroup | - | Buy | Initialise |
10
Summit Therapeutics Financial Forecast
Summit Therapeutics Revenue Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 18 | Sep 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | - | - | - | - | - | - | - | - | $57.00K | $192.00K | $185.00K | $181.00K | $170.00K | $312.96K | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | $9.74M | $3.22M | $3.19M | $2.90M | $3.16M | $3.21M | $4.22M | $3.83M | $177.69K | $5.30M | $21.25M |
High Forecast | - | - | - | - | - | - | - | $9.74M | $3.22M | $3.19M | $2.90M | $3.16M | $3.21M | $4.22M | $3.83M | $213.23K | $6.37M | $25.49M |
Low Forecast | - | - | - | - | - | - | - | $9.74M | $3.22M | $3.19M | $2.90M | $3.16M | $3.21M | $4.22M | $3.83M | $142.15K | $4.24M | $17.00M |
# Analysts | - | - | - | - | - | - | - | 1 | 7 | 13 | 13 | 7 | 7 | 9 | 8 | 14 | 7 | 11 |
Surprise % | - | - | - | - | - | - | - | - | 0.02% | 0.06% | 0.06% | 0.06% | 0.05% | 0.07% | - | - | - | - |
Forecast
Summit Therapeutics EBITDA Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 18 | Sep 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 1 | 7 | 13 | 13 | 7 | 7 | 9 | 8 | 14 | 7 | 11 |
EBITDA | - | - | - | - | - | - | - | - | $-23.75M | $-17.00M | $-13.27M | $-17.34M | $-14.91M | $-6.90M | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | $-5.84M | $-9.46M | $-1.91M | $-1.74M | $-1.47B | $-1.93M | $-2.53M | $-2.30M | $-6.91M | $-8.64M | $11.09M |
High Forecast | - | - | - | - | - | - | - | $-5.84M | $-7.57M | $-1.91M | $-1.74M | $-1.18B | $-1.93M | $-2.53M | $-2.30M | $-5.53M | $-6.91M | $13.31M |
Low Forecast | - | - | - | - | - | - | - | $-5.84M | $-11.35M | $-1.91M | $-1.74M | $-1.77B | $-1.93M | $-2.53M | $-2.30M | $-8.30M | $-10.36M | $8.87M |
Surprise % | - | - | - | - | - | - | - | - | 2.51% | 8.89% | 7.63% | 0.01% | 7.74% | 2.72% | - | - | - | - |
Forecast
Summit Therapeutics Net Income Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 18 | Sep 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 1 | 7 | 13 | 13 | 7 | 7 | 9 | 8 | 14 | 7 | 11 |
Net Income | - | - | - | - | - | - | - | - | $-25.10M | $-18.05M | $-13.44M | $-17.70M | $-15.28M | $-6.11M | - | - | - | - |
Avg Forecast | $-66.82M | $-57.28M | $-51.55M | $-45.82M | $-44.21M | $-36.25M | $-34.60M | $1.20B | $-9.72M | $-87.08M | $-109.19M | $-1.51B | $-51.11M | $-14.67M | $-118.98M | $-7.66M | $-7.99M | $12.24M |
High Forecast | $-66.82M | $-57.28M | $-51.55M | $-45.82M | $-39.96M | $-36.25M | $-34.60M | $1.20B | $-7.78M | $-87.08M | $-109.19M | $-1.20B | $-51.11M | $-14.67M | $-118.98M | $-6.12M | $-6.39M | $14.69M |
Low Forecast | $-66.82M | $-57.28M | $-51.55M | $-45.82M | $-45.88M | $-36.25M | $-34.60M | $1.20B | $-11.67M | $-87.08M | $-109.19M | $-1.81B | $-51.11M | $-14.67M | $-118.98M | $-9.19M | $-9.59M | $9.79M |
Surprise % | - | - | - | - | - | - | - | - | 2.58% | 0.21% | 0.12% | 0.01% | 0.30% | 0.42% | - | - | - | - |
Forecast
Summit Therapeutics SG&A Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 18 | Sep 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 1 | 7 | 13 | 13 | 7 | 7 | 9 | 8 | 14 | 7 | 11 |
SG&A | - | - | - | - | - | - | - | - | $5.98M | $4.18M | $5.80M | $7.46M | $5.77M | $646.95K | - | - | - | - |
Avg Forecast | - | - | - | - | - | - | - | $173.48M | $2.38M | $56.78M | $51.60M | $56.24M | $57.15M | $75.22M | $68.18M | $3.16M | $3.65M | $2.79M |
High Forecast | - | - | - | - | - | - | - | $173.48M | $2.86M | $56.78M | $51.60M | $56.24M | $57.15M | $75.22M | $68.18M | $3.80M | $4.39M | $3.35M |
Low Forecast | - | - | - | - | - | - | - | $173.48M | $1.91M | $56.78M | $51.60M | $56.24M | $57.15M | $75.22M | $68.18M | $2.53M | $2.92M | $2.23M |
Surprise % | - | - | - | - | - | - | - | - | 2.51% | 0.07% | 0.11% | 0.13% | 0.10% | 0.01% | - | - | - | - |
Forecast
Summit Therapeutics EPS Forecast
Quarter
Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | Jun 18 | Sep 17 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
# Analysts | - | - | - | - | - | - | - | 1 | 7 | 13 | 13 | 7 | 7 | 9 | 8 | 14 | 7 | 11 |
EPS | - | - | - | - | - | - | - | - | $-0.28 | $-0.22 | $-0.18 | $-0.26 | $-0.23 | $-0.09 | - | - | - | - |
Avg Forecast | $-0.09 | $-0.08 | $-0.07 | $-0.06 | $-0.06 | $-0.05 | $-0.05 | $1.65 | $-0.13 | $-0.12 | $-0.15 | $-0.19 | $-0.07 | $-0.02 | $-0.17 | $-0.67 | $-0.75 | $0.30 |
High Forecast | $-0.09 | $-0.08 | $-0.07 | $-0.06 | $-0.05 | $-0.05 | $-0.05 | $1.65 | $-0.13 | $-0.12 | $-0.15 | $-0.19 | $-0.07 | $-0.02 | $-0.17 | $-0.54 | $-0.59 | $0.36 |
Low Forecast | $-0.09 | $-0.08 | $-0.07 | $-0.06 | $-0.06 | $-0.05 | $-0.05 | $1.65 | $-0.13 | $-0.12 | $-0.15 | $-0.19 | $-0.07 | $-0.02 | $-0.17 | $-0.80 | $-0.90 | $0.24 |
Surprise % | - | - | - | - | - | - | - | - | 2.15% | 1.79% | 1.17% | 1.40% | 3.19% | 4.38% | - | - | - | - |
Forecast
Summit Therapeutics Peer Comparison by Price Target
Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
---|---|---|---|---|---|
ELEV | Elevation Oncology | $0.61 | $9.00 | 1375.41% | Buy |
NKTX | Nkarta | $2.44 | $21.60 | 785.25% | Buy |
ZURA | Zura Bio | $2.93 | $10.00 | 241.30% | Buy |
CGEM | Cullinan Oncology | $12.22 | $31.50 | 157.77% | Buy |
KZR | Kezar Life Sciences | $7.62 | $17.50 | 129.66% | Buy |
SMMT | Summit Therapeutics | $18.42 | $35.00 | 90.01% | Buy |
KRON | Kronos Bio | $0.87 | $1.63 | 87.36% | Buy |